Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
7.47
Nov 16 • 3:59 PM ET Dollar change-0.97 Percentage change(-11.54%)
Aftermarket Close
7.55
Aftermarket • 7:58 PM ET Dollar change+0.08 Percentage change(1.06%)
Index
RUT
Market Cap
1.29B
Enterprise Value
1.12B
Income
-125.67M
Sales
1.49M
Book/sh
1.27
Cash/sh
1.01
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
140
IPO
Jul 22, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
866.62
P/B
5.89
P/C
7.43
P/FCF
-
EV/EBITDA
-
EV/Sales
752.23
Quick Ratio
9.64
Current Ratio
9.64
Debt/Eq
0.02
LT Debt/Eq
0.01
Option/Short
Yes / Yes
EPS (ttm)
-0.79
EPS next Y
-0.75
EPS next Q
-0.20
EPS this Y
6.31%
EPS next Y
5.05%
EPS next 5Y
3.07%
EPS past 3/5Y
9.99% -9.45%
Sales past 3/5Y
-21.31% -10.14%
EPS Y/Y TTM
12.12%
Sales Y/Y TTM
-47.18%
EPS Q/Q
2.95%
Sales Q/Q
-19.58%
Insider Own
13.68%
Insider Trans
0.05%
Inst Own
87.43%
Inst Trans
18.66%
ROA
-51.87%
ROE
-58.59%
ROIC
-57.17%
Gross Margin
-635.71%
Oper. Margin
-9155.35%
Profit Margin
-8451.31%
SMA20
-24.67%
SMA50
-22.35%
SMA200
9.07%
Trades
Shs Outstand
172.38M
Shs Float
149.12M
52W High
12.54 -40.41%
52W Low
2.24 233.71%
Volatility
11.33% 10.80%
ATR (14)
1.05
RSI (14)
37.75
Beta
2.21
Rel Volume
2.05
Avg Volume
3.84M
Volume
7,871,680
Perf Week
-30.79%
Perf Month
-9.39%
Perf Quarter
-15.54%
Perf Half Y
51.16%
Perf YTD
114.18%
Perf Year
165.07%
Perf 3Y
437.77%
Perf 5Y
-38.07%
Perf 10Y
-
Prev Close
8.45
Price
7.47
Change %
-11.54%
Consensus
Strong Buy
Avg. Price Target
$15.09
Implied Upside
+101.9%
Analysts16incl. previous ratings
Rating Distribution12 Buy · 3 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 29, 2026Initiated
JEF logoJJefferies
Buy$14+87.3%
Jun 04, 2026Initiated
LLeerink Partners
Outperform$12+60.5%
May 28, 2026Initiated
BBTIG Research
Buy$9+20.4%
Jan 08, 2026Downgrade
MS logoMMorgan Stanley
Overweight → Equal-Weight$4.32-42.2%
Oct 02, 2025Initiated
JPM logoJJP Morgan
Overweight
Jul 03, 2025Resumed
MS logoMMorgan Stanley
Overweight$7-6.4%
Jan 22, 2025Initiated
NNeedham
Buy$9+20.4%
Oct 02, 2024Initiated
GGuggenheim
Buy$10+33.8%
Jul 03, 2024Initiated
MS logoMMorgan Stanley
Overweight$7-6.4%
Mar 14, 2024Initiated
BNS logoBScotiabank
Sector Outperform$13+73.9%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Szela Mary TDirectorJun 30 '26Buy11.5412,900148,86621,300Jul 06 04:06 PM
Pangalos Menelas NDirectorMay 13 '26Buy5.3637,453200,748232,308May 13 04:05 PM
Busch AndreasChief Innovation OfficerMar 12 '26Buy2.29100,000229,000421,446Mar 16 04:17 PM
Pangalos Menelas NDirectorFeb 27 '26Buy2.7475,095205,760189,055Mar 03 04:13 PM
McClain SeanChief Executive OfficerFeb 23 '26Option Exercise1.21396,399479,6438,730,966Feb 25 06:05 PM
McClain SeanChief Executive OfficerFeb 02 '26Sale2.9926,76180,0158,334,567Feb 04 04:52 PM
Jonasson ZachariahCFO / CBOFeb 02 '26Sale2.9917,49652,313383,538Feb 04 04:51 PM
VAN HOUTEN FRANSDirectorDec 05 '25Buy3.7240,000148,80063,320Dec 09 04:04 PM
Absci Corp. engages in drug discovery with generative design to create biologics for patients. Its platform combines AI models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. The firm has its own pipeline of AI designed therapeutics including ABS-201 and ABS-202. Absci Corp was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.
FounderMr. Sean McClain
Chief Business Officer & CFODr. Zachariah Jonasson Ph.D.
Senior VP & Chief Accounting OfficerMr. Todd Bedrick CPA
CVP of Finance & Head of Investor RelationsMr. Alexander Khan CPA
Chief Legal OfficerMs. Shelby Walker J.D.